Inventiva (NASDAQ:IVA) Shares Gap Up After Analyst Upgrade

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price gapped up prior to trading on Tuesday after Leerink Partnrs upgraded the stock to a strong-buy rating. The stock had previously closed at $5.45, but opened at $5.71. Inventiva shares last traded at $5.6260, with a volume of 120,111 shares trading hands.

A number of other research firms have also issued reports on IVA. HC Wainwright upped their target price on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. UBS Group began coverage on shares of Inventiva in a research report on Wednesday, January 7th. They set a “buy” rating and a $12.00 price target on the stock. Leerink Partners started coverage on shares of Inventiva in a report on Monday. They issued an “outperform” rating and a $12.00 price objective for the company. Guggenheim decreased their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Inventiva in a research report on Tuesday, September 30th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $16.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC increased its stake in Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after acquiring an additional 5,843 shares during the last quarter. Creative Planning purchased a new position in shares of Inventiva during the 2nd quarter worth $32,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the 3rd quarter worth about $116,000. Finally, Millennium Management LLC acquired a new stake in shares of Inventiva during the 3rd quarter worth about $649,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Price Performance

The firm’s fifty day moving average is $4.42 and its 200-day moving average is $4.53.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.